In various cancer types, a high tumor mutational burden is linked to longer survival following treatment with immune checkpoint inhibitors.25 However, we observed no correlation between SPEF1 expression, mutational burden status, and patient survival. The gene discussed is SPEF1; the disease is neoplasm.